

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CSPC PHARMACEUTICAL GROUP LIMITED**

**石藥集團有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 1093)**

### **VOLUNTARY ANNOUNCEMENT**

#### **RECOMBINANT FULLY HUMAN ANTI-ACTRIIA/IIB MONOCLONAL ANTIBODY (JMT206) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.**

The Board of Directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the recombinant fully human anti-ActRIIA/IIB monoclonal antibody (JMT206) (the “**Product**”) developed by the Group has obtained approval from the U.S. Food and Drug Administration (FDA) to conduct clinical trials in the U.S. The Product also obtained approval from the National Medical Products Administration of the People’s Republic of China in November 2025 to conduct clinical trials in China.

The Product can simultaneously and specifically bind to activin receptor type IIA (ActRIIA) and type IIB (ActRIIB), and block the binding of activin A, myostatin (GDF8), and growth differentiation factor 11 (GDF11) to activin type II receptor (ActRII), thereby inhibiting downstream signaling pathway activation, reducing muscle loss and promoting the maintenance and growth of skeletal muscle to achieve the effect of increasing muscle mass and reducing fat. Meanwhile, the Product can also enhance the quality of weight loss outcomes achieved with GLP-1 receptor agonists. The indication for this clinical trial approval is weight management for individuals with obesity or overweight and at least one weight-related comorbidity.

Preclinical studies showed that the Product exhibited high bioavailability as well as favorable efficacy and safety profiles, providing a promising clinical development value.

By order of the Board  
**CSPC Pharmaceutical Group Limited**  
**CAI Dong Chen**  
*Chairman*

Hong Kong, 10 December 2025

*As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping and Mr. QU Zhiyong as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.*